Cabrol C, Gandjbakhch I, Pavie A, Cabrol A, Mattei M F, Liénhart A, Gluckmann J C, Rottembourg J
Arch Mal Coeur Vaiss. 1984 Dec;77(13):1427-33.
Since 1968, 320 patients with severe irreversible myocardial failure, have been referred to our department for transplantation; 78 p. 100 had dilated cardiomyopathies; 14 p. 100 had ischaemic heart disease and 8 p. 100 had valvular heart disease. One hundred and five patients had absolute contra-indications and were excluded (pulmonary hypertension, diabetes, gastro-duodenal ulcer, age, or other major organic disease). Of the remaining 215 patients, only 82 were transplanted because of the limited number of available donor hearts. The most commonly used technique was orthotopic grafting as described by Lower and Shumway; Barnard's method of heterotopic grafting was used in 1 case and a block heart and lung transplantation by Reitz and Shumway's method was performed in 3 cases. The main postoperative complications, apart from technical problems (7 deaths), were related to rejection (107 episodes, 27 deaths), infection (82 episodes, 13 deaths), atherosclerosis of the graft (4 cases, 2 deaths, 1 retransplantation) and malignant tumours (3 deaths). After transplantation, 82 p. 100 of patients were discharged after an average hospital stay of 2 months; 47 p. 100 survived the first year and lead almost normal socio-professional activities. Thirty patients are still alive, the longest postoperative survival being 9 years. Significant advances have been made in the last 3 years. Classical immuno-suppressor therapy (steroids, azathioprine, horse antilymphocytic serum) has given way to more effective antilymphocytic sera and more powerful immuno-suppressor drugs (cyclosporine A). This treatment has greatly changed the postoperative course of events. Rejection phenomena, though still as common, are much less serious and, above all, more insidious.(ABSTRACT TRUNCATED AT 250 WORDS)
自1968年以来,320例严重不可逆性心肌衰竭患者被转诊至我科接受移植治疗;其中78%患有扩张型心肌病;14%患有缺血性心脏病,8%患有心脏瓣膜病。105例患者存在绝对禁忌证而被排除(肺动脉高压、糖尿病、胃十二指肠溃疡、年龄或其他重大器质性疾病)。在其余215例患者中,由于可用供体心脏数量有限,仅有82例接受了移植。最常用的技术是Lower和Shumway描述的原位移植;1例采用了Barnard的异位移植方法,3例采用Reitz和Shumway方法进行了整块心肺移植。除技术问题(7例死亡)外,主要术后并发症与排斥反应(107次发作,27例死亡)、感染(82次发作,13例死亡)、移植血管动脉粥样硬化(4例,2例死亡,1例再次移植)和恶性肿瘤(3例死亡)有关。移植后,82%的患者平均住院2个月后出院;47%的患者存活了第一年,并几乎能够正常地进行社会职业活动。30例患者仍然存活,术后最长存活时间为9年。在过去3年中取得了重大进展。经典的免疫抑制疗法(类固醇、硫唑嘌呤、马抗淋巴细胞血清)已被更有效的抗淋巴细胞血清和更强效的免疫抑制药物(环孢素A)所取代。这种治疗方法极大地改变了术后的病程。排斥反应现象虽然仍然常见,但严重程度大大降低,最重要的是,变得更加隐匿。(摘要截选至250词)